Novanta (NOVT) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for Novanta (NOVT): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why NOVT has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with NOVT. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
Novanta trades at a rich valuation, with a trailing price-to-earnings ratio near 100x and a forward multiple around 41x, reflecting the market's view of it as a durable, high-margin precision-technology compounder. GAAP earnings are held down by acquisition-related amortization and stock compensation, so the company and analysts emphasize adjusted EPS and adjusted EBITDA. That premium multiple means the shares can react strongly to any change in the growth or margin trajectory.
Is there a 2030 forecast for NOVT?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering NOVT do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.
On the figures we hold as of October 2026, NOVT trades at about 94.7 times trailing earnings and 34.3 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.
That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Novanta can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move NOVT from here
In short: the drivers cited most often are Medical Solutions demand, Automation and robotics, Acquisitions and margin expansion. The risk cited most often against it is novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the NOVT is it a buy page. This page deliberately stops at the numbers.
Investing in Novanta with AI
Connect the broker you already use and ask Walnut's AI how NOVT fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Novanta (NOVT)?
+
There is no meaningful consensus price target for NOVT, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does NOVT have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move NOVT?
+
The drivers and the risks are laid out on this page and in more depth on the NOVT "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a October 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.